Allucent Government Services (Us) LLC

Allucent Government Services (Us) LLC, formerly known as Pharm-Olam, LLC, is a for-profit clinical research organization specializing in comprehensive services to support clinical trials and medical countermeasure development for the U.S. federal government. The company offers expertise across the entire clinical trial lifecycle, from preclinical studies through late-stage trials, with a focus on infectious diseases research, public health preparedness, and regulatory support for biopharmaceutical product development. Allucent's core capabilities include clinical trial planning and execution, subject matter expert consultation, specimen collection and management, and support for the development of medical countermeasures against chemical, biological, radiological, nuclear, pandemic influenza, and emerging infectious disease threats.

Allucent has been awarded numerous prime contracts and task orders from various federal agencies, primarily within the Department of Health and Human Services (HHS) and the Department of Defense (DoD). For HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR), Allucent has provided clinical trial planning and execution services, subject matter expert consultation, and specimen collection support under a $400 million indefinite delivery contract. Specific task orders have included a $343.2 million award for clinical trial planning and execution, a $34.1 million award for specimen collection services, and smaller awards for clinical studies network support. The company has also received contracts from the National Institutes of Health (NIH) for subject matter expert consulting on drug metabolism pharmacokinetics and to support infectious disease clinical trials under the Early Phase Clinical Trial Units program. Additionally, Allucent was awarded two other transaction agreements from the Army, totaling nearly $89 million, for prototype clinical trials involving COVID-19 treatments and military facility trials. These contracts have primarily been performed at Allucent's division in Houston, Texas, and have not been associated with any set-aside designations.

Allucent holds three significant federal contract Indefinite Delivery Vehicles (IDVs). The first is a $30 million single-award IDV from NIH's National Institute of Allergy and Infectious Diseases for preclinical services supporting biopharmaceutical product development, including planning, assay development, manufacturing, and regulatory activities. The second is a $346.6 million multiple-award IDV under the Early Phase Clinical Trial Units program to conduct Phase 0-III clinical trials for infectious disease products. The third and largest is a $550 million single-award IDV from ASPR for clinical trial planning and execution services, which serves as the vehicle for multiple delivery orders supporting ASPR's medical countermeasure programs. These IDVs collectively demonstrate Allucent's comprehensive capabilities in supporting the development of medical countermeasures for various threats, as well as its ability to efficiently conduct domestic and international clinical trials for various investigational products. Task orders under these IDVs have been awarded by agencies such as NIAID and ASPR, further solidifying Allucent's role as a key partner in federal efforts to advance medical research and preparedness.